Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
Funding Opportunity PAR-20-300 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric ?precision therapeutics. (Source: NIH Fun...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2020 Category: Research Source Type: funding
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
Funding Opportunity PAR-20-299 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics. (Source: NIH Fund...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2020 Category: Research Source Type: funding
Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P50 Clinical Trial Optional)
Funding Opportunity RFA-HD-21-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to form Centers of Excellence in Therapeutics (CETs) as part of the NICHDs Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. By serving as a national resource, it will aggregate, present, and expand the available knowled...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 3, 2020 Category: Research Source Type: funding
Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P30 Clinical Trial Not Allowed)
Funding Opportunity RFA-HD-21-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to form the Knowledge and Research Coordination Center (KRCC) of the NICHDs Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. By serving as a national resource, it will aggregate, present, and expand the available knowle...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 3, 2020 Category: Research Source Type: funding
Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-233 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinic...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 16, 2020 Category: Research Source Type: funding
Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-232 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of pati...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 16, 2020 Category: Research Source Type: funding
Catalyzing Innovation in Pediatric Pharmacology Clinical Trial Design and Resource Access (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-161 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to a consultative resource for planning activities and concept development for single or multi-site investigator initiated clinical trials that address gaps in pediatric drug development and that align with priorities identified in the Best Pharmaceuticals for Children Act (BPCA) Program. The FOA will support the development of clinical trials concepts of future well-designed clinical trials that require non-traditional designs in pediatric therape...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 2, 2020 Category: Research Source Type: funding
Postdoctoral Training in Pediatric Clinical Pharmacology (T32 Clinical Trial Not Allowed)
Funding Opportunity RFA-HD-21-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites grant applications from institutions/organizations that propose to develop clinician-scientists and others who will be leaders in the field of pediatric clinical pharmacology research. Individuals in these programs should receive training and experience in the methods and conduct of basic and clinical research, in order to qualify them to perform such studies independently. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 12, 2020 Category: Research Source Type: funding
Seeking Your Input on Simplifying Review Criteria
Bruce Reed, Ph.D., Deputy Director of the NIH Center for Scientific Review
Guest post by Bruce Reed, Deputy Director of the NIH Center for Scientific Review, originally released on the Review Matters blog
Over the past several years we have heard consistent concerns about the complexity of review criteria and administrative load of peer review. CSR shares the concern that the current set of standards has the unintended consequence of dividing reviewer attention among too many questions, thus reducing focus on scientific merit and increasing reviewer burden. Each element was intended make review better, but we w...
Source: NIH Extramural Nexus - February 27, 2020 Category: Research Authors: Bruce Reed Tags: blog Open Mike CSR Peer review Source Type: funding
HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-031 from the NIH Guide for Grants and Contracts. This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids. Two critical phases of pre-clinical investigation are supported. Phase I: the identification and rigorous validation of candidate targets; Phase II: development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue. S...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 24, 2020 Category: Research Source Type: funding
Notice to Extend the Expiration Date for PAR-18-214 "Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional)"
Notice NOT-HD-20-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 16, 2020 Category: Research Source Type: funding
Notice to Extend the Expiration Date for PAR-18-215 "Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional)"
Notice NOT-HD-20-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 16, 2020 Category: Research Source Type: funding
Immune Tolerance Network (UM1 Clinical Trial Required)
Funding Opportunity RFA-AI-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Immune Tolerance Network. The major goal of this Network is to develop tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated consequences of allotransplantation. The scope of research to be carried out includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 6, 2019 Category: Research Source Type: funding
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Funding Opportunity RFA-CA-19-056 from the NIH Guide for Grants and Contracts. The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2019 Category: Research Source Type: funding
Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-20-019 from the NIH Guide for Grants and Contracts. This funding opportunity aims to support the development and the application of novel pharmacological approaches to manipulate signaling mediated by endogenous opioid receptors in defined circuits, cell-types or subcellular compartments in live organisms. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 30, 2019 Category: Research Source Type: funding
